DSM Biologics and Crucell N.V. have achieved a record yield of more than 27 grams per liter in the production of IgG antibodies using PER.C6 technology. In March 2008 a yield of 15 grams per liter was reported. Higher yields can mean lower production costs and reduced risk in drug development. Also, the glycosylation of monoclonal antibodies and proteins, produced using PER.C6 technology, is fully human.

Scientists at Percivia PER.C6 Development Center , a joint venture between DSM and Crucell, have shown that they can reproduce the manufacture a record amount of product with more than 95% viability and unchanged product quality. This was achieved using standard bioreactor equipment and readily available cell culture medium. The result of this effort provides the biotechnology industry with a reliable production platform to economically manufacture large amounts of therapeutic proteins more easily.

Marcel Lubben, vice president business development at DSM Biologics, said, “We are extremely pleased with this achievement. This milestone coincides with our commitment to provide the most inherently robust manufacturing platform and ensure the utmost product quality for protein manufacturing. Our mission of only the best quality for manufacturing is echoed by the PER.C6 technology platform.”